- Home
- KYNB vs ESLA Comparison
KYNB vs ESLA Comparison
Compare KYNB & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | ESLA |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 32.0M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KYNB | ESLA |
|---|---|---|
| Price | $8.11 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 12.5K | ★ 23.6K |
| Earning Date | 05-04-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9552.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $0.68 |
| 52 Week High | $9.58 | $3.15 |
Technical Indicators
Market Signals| Indicator | KYNB | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | N/A |
| Support Level | $6.61 | N/A |
| Resistance Level | $8.99 | N/A |
| Average True Range (ATR) | 0.31 | 0.00 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 99.24 | 0.00 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.